Recombinant Human ITLN1/Omentin, N-His from ProteoGenix; catalogue ARO-P13218; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human ITLN1, also known as Omentin, is a protein that is produced through recombinant DNA technology. It is a member of the adipokine family and is primarily expressed in adipose tissue. Omentin has been found to play a role in various physiological processes, including glucose metabolism, inflammation, and cardiovascular health. In this article, we will delve into the structure, activity, and applications of Recombinant Human ITLN1/Omentin.
Recombinant Human ITLN1 is a glycoprotein with a molecular weight of approximately 34 kDa. It is composed of 313 amino acids and has a predicted secondary structure consisting of alpha-helices and beta-sheets. The protein contains two distinct domains, an N-terminal domain and a C-terminal domain, connected by a flexible linker region. The N-terminal domain is responsible for the binding of Omentin to its receptor, while the C-terminal domain is involved in the regulation of its activity.
Omentin has been found to have various activities in the body, making it a promising therapeutic target for various diseases. One of its main functions is its role in glucose metabolism. Omentin has been shown to enhance insulin sensitivity and glucose uptake in adipocytes, leading to improved glucose homeostasis. This activity of Omentin is particularly important in the development of insulin resistance and type 2 diabetes.
In addition to its role in glucose metabolism, Omentin also has anti-inflammatory properties. It has been shown to reduce the production of pro-inflammatory cytokines and inhibit the activation of inflammatory pathways in various cell types. This anti-inflammatory activity makes Omentin a potential therapeutic agent for conditions such as inflammatory bowel disease and rheumatoid arthritis.
Moreover, Omentin has been found to have a protective effect on cardiovascular health. It has been shown to inhibit the proliferation of smooth muscle cells and prevent the formation of atherosclerotic plaques. Omentin also has vasodilatory properties, which can help improve blood flow and prevent hypertension.
The potential applications of Recombinant Human ITLN1/Omentin are vast, given its diverse range of activities. One of the most promising applications is in the treatment of type 2 diabetes. Omentin has been shown to improve insulin sensitivity and glucose uptake, making it a potential therapeutic option for managing this disease. Additionally, Omentin may also have a role in the prevention of cardiovascular complications associated with diabetes.
Furthermore, Omentin has potential applications in the treatment of inflammatory diseases. Its anti-inflammatory properties make it a potential therapeutic option for conditions such as inflammatory bowel disease, rheumatoid arthritis, and atherosclerosis. Omentin may also have a role in the treatment of obesity, as it has been found to regulate adipogenesis and fat accumulation.
In the field of diagnostics, Recombinant Human ITLN1/Omentin can be used as an antigen for the development of diagnostic tests for various diseases. Its expression in adipose tissue and its involvement in various physiological processes make it a potential biomarker for conditions such as obesity, diabetes, and cardiovascular disease.
Recombinant Human ITLN1/Omentin is a promising protein with diverse physiological activities. Its structure, activity, and potential applications make it a valuable target for therapeutic and diagnostic purposes. Further research on the protein and its mechanisms of action may lead to the development of novel treatments for various diseases.
ProteoGenix catalogue number ARO-P13218. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 27.18 kDa; Fragment: Cys31-Gly253; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
